Publication at First Faculty of Medicine |
2018
Abstract
Gliflozins are one of the most promising groups of antidiabetic drugs. A factor contributing to their success are primarily the outcomes of cardiovascular studies, with empagliflozin in particular, showing a significant effect on reducing the rates of cardiovascular events, heart failure and diabetes-related renal complications.
Partly similar outcomes were reported for canagliflozin; this, however, at the cost of a significantly increased risk of lower limb amputation. These results have projected into increasing global sales of gliflozins, reaching tens of percent annually in absolute terms, with empagliflozin logically taking the biggest share in the market.
Time and ongoing studies will show possible future uses of gliflozins.